Adagene Inc. (Nasdaq: ADAG) is a pioneering biotechnology company established in 2012, with a commitment to transforming the design and discovery of antibody-based cancer immunotherapies. The company’s slogan, "Redefining the design and discovery of therapeutic antibodies," underscores its innovative approach in this specialized field.
Central to Adagene's advancements is its proprietary DPL platform, which includes NEObody, SAFEbody™, and POWERbody™ technologies. These elements facilitate the creation of novel antibodies, tailored to address critical unmet patient needs. The company's strategic collaborations with prominent global partners highlight its ability to leverage cutting-edge technologies in novel immunotherapy programs.
Adagene recently secured a $70.00M Post IPO Equity investment on 01 April 2026 from notable investors including Invus, Columbia Threadneedle Investments, Janus Henderson Investors, Deerfield, and Sirenia Aps, indicating strong confidence in its potential to revolutionize cancer treatment.
